ArsenalBio
NEWS
Last month, biotech and pharma companies making or planning workforce cuts included three whose reductions will more than halve their workforces. Blueprint Medicines’ layoffs will affect the most employees.
After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as part of a strategic shift to focus the company’s R&D efforts on in vivo CAR T therapies.
Genentech and privately-held Arsenal Biosciences forged a multi-year collaboration to identify critical success circuits in T cell-based therapies for solid tumors.
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
ArsenalBio has entered into a multi-year discovery partnership with Bristol Myers Squibb to develop next-generation T cell therapies for solid tumors.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
JOBS
IN THE PRESS